Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for Marker Therapeutics (MRKR) over the last 7 years, with Q3 2025 value amounting to $138064.0.

  • Marker Therapeutics' Interest & Investment Income rose 5059.17% to $138064.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $502324.0, marking a year-over-year decrease of 1103.06%. This contributed to the annual value of $437010.0 for FY2024, which is 1894.58% down from last year.
  • Marker Therapeutics' Interest & Investment Income amounted to $138064.0 in Q3 2025, which was up 5059.17% from $128025.0 recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Interest & Investment Income peaked at $218085.0 during Q3 2023, and registered a low of $3117.0 during Q1 2022.
  • For the 4-year period, Marker Therapeutics' Interest & Investment Income averaged around $110187.3, with its median value being $109410.0 (2022).
  • As far as peak fluctuations go, Marker Therapeutics' Interest & Investment Income skyrocketed by 261588.07% in 2023, and later crashed by 6337.22% in 2024.
  • Marker Therapeutics' Interest & Investment Income (Quarter) stood at $109410.0 in 2022, then surged by 84.02% to $201339.0 in 2023, then tumbled by 63.37% to $73746.0 in 2024, then surged by 87.22% to $138064.0 in 2025.
  • Its Interest & Investment Income was $138064.0 in Q3 2025, compared to $128025.0 in Q2 2025 and $162489.0 in Q1 2025.